Loading...
•
Mar 31
Jaguar Health Q1 2025 Earnings Report
Posted lower revenue and deeper losses due to declining product sales and increased expenses.
Key Takeaways
Jaguar Health reported a 6% year-over-year revenue decline in Q1 2025, driven by reduced product sales. Operating and net losses widened compared to the prior year, and non-GAAP recurring EBITDA also declined. Despite the financial setbacks, Mytesi prescription volume grew slightly year-over-year.
Revenue for Q1 2025 was $2,214,000, down 6% YoY and 37% QoQ.
Net loss attributable to common stockholders was $10,465,000.
EPS came in at -$16.70 per share.
Mytesi prescription volume increased 1.8% YoY but fell 13.5% from Q4.
Jaguar Health
Jaguar Health
Forward Guidance
Jaguar Health aims to advance development programs including crofelemer for rare diseases and anticipates additional trial data throughout 2025.
Positive Outlook
- POC data suggests crofelemer may reduce need for parenteral nutrition
- FDA meeting scheduled for Q2 2025 on OnTarget trial subgroup data
- Prescription volume for Mytesi grew YoY despite revenue drop
- License revenue stream initiated with European partner
- Continued investment in clinical research and regulatory milestones
Challenges Ahead
- Overall revenue declined 6% YoY and 37% QoQ
- Net loss widened to $10.5 million in Q1 2025
- Sales and marketing costs increased $1.1 million YoY
- Non-GAAP recurring EBITDA loss rose to $9.7 million
- No detailed segment or geographic revenue data disclosed